355 related articles for article (PubMed ID: 15013845)
1. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
Uchiyama S; Yamaguchi M
Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845
[TBL] [Abstract][Full Text] [Related]
2. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
Yamaguchi M; Uchiyama S
Int J Mol Med; 2004 Jul; 14(1):81-5. PubMed ID: 15202020
[TBL] [Abstract][Full Text] [Related]
3. Regucalcin stimulates osteoclast-like cell formation in mouse marrow cultures.
Yamaguchi M; Uchiyama S
J Cell Biochem; 2005 Mar; 94(4):794-803. PubMed ID: 15578574
[TBL] [Abstract][Full Text] [Related]
4. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
5. beta-Cryptoxanthin stimulates cell proliferation and transcriptional activity in osteoblastic MC3T3-E1 cells.
Uchiyama S; Yamaguchi M
Int J Mol Med; 2005 Apr; 15(4):675-81. PubMed ID: 15754031
[TBL] [Abstract][Full Text] [Related]
6. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.
Matsuzaki K; Udagawa N; Takahashi N; Yamaguchi K; Yasuda H; Shima N; Morinaga T; Toyama Y; Yabe Y; Higashio K; Suda T
Biochem Biophys Res Commun; 1998 May; 246(1):199-204. PubMed ID: 9600092
[TBL] [Abstract][Full Text] [Related]
7. TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF.
Sells Galvin RJ; Gatlin CL; Horn JW; Fuson TR
Biochem Biophys Res Commun; 1999 Nov; 265(1):233-9. PubMed ID: 10548519
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol.
Ishizuka K; Hirukawa K; Nakamura H; Togari A
Neurosci Lett; 2005 Apr; 379(1):47-51. PubMed ID: 15814197
[TBL] [Abstract][Full Text] [Related]
10. Osteoclastogenesis is decreased by cysteine proteinase inhibitors.
Brage M; Lie A; Ransjö M; Kasprzykowski F; Kasprzykowska R; Abrahamson M; Grubb A; Lerner UH
Bone; 2004 Mar; 34(3):412-24. PubMed ID: 15003789
[TBL] [Abstract][Full Text] [Related]
11. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
13. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
Dai SM; Nishioka K; Yudoh K
Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH.
Kwak HB; Lee SW; Li YJ; Kim YA; Han SY; Jhon GJ; Kim HH; Lee ZH
Biochem Pharmacol; 2004 Apr; 67(7):1239-48. PubMed ID: 15013839
[TBL] [Abstract][Full Text] [Related]
15. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
Ishida M; Amano S
J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
[TBL] [Abstract][Full Text] [Related]
16. beta-cryptoxanthin stimulates cell differentiation and mineralization in osteoblastic MC3T3-E1 cells.
Uchiyama S; Yamaguchi M
J Cell Biochem; 2005 Aug; 95(6):1224-34. PubMed ID: 15962303
[TBL] [Abstract][Full Text] [Related]
17. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone.
Faucheux C; Horton MA; Price JS
J Bone Miner Res; 2002 Mar; 17(3):455-64. PubMed ID: 11874237
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
Woo JT; Nakagawa H; Krecic AM; Nagai K; Hamilton AD; Sebti SM; Stern PH
Biochem Pharmacol; 2005 Jan; 69(1):87-95. PubMed ID: 15588717
[TBL] [Abstract][Full Text] [Related]
19. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
20. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
